J B Chemicals and Pharmaceuticals Limited has officially announced the cessation of Mr. Nikhil Chopra as Chief Executive Officer and Key Managerial Personnel, effective from the closing of business hours on March 31, 2026. The pharmaceutical company made this disclosure under Regulation 30 of the Securities and Exchange Board of India Listing Regulations on April 1, 2026.

Leadership Transition Details

The company's announcement follows an earlier intimation dated January 21, 2026, which disclosed Chopra's resignation as Whole-time Director from the conclusion of the Board meeting held on that date. However, he continued serving as CEO until March 31, 2026, ensuring a structured transition period.

Resignation Background

In his resignation letter dated January 21, 2026, Chopra outlined a phased departure approach. His resignation as Whole-time Director and member of Board committees became effective immediately upon the conclusion of the Board meeting where the letter was presented. The CEO role, however, continued until March 31, 2026, allowing for operational continuity.

Chopra cited personal reasons and the pursuit of other professional opportunities as the primary factors behind his decision. He explicitly confirmed that no other reasons contributed to his resignation beyond those stated in his letter.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the Listing Regulations and the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The announcement was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary, ensuring proper corporate governance protocols were followed.

Company Operations

J.B. Chemicals & Pharmaceuticals Limited, incorporated under CIN L24390GJ1976PLC173077, operates from its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai. The company maintains its commitment to pharmaceutical operations under the tagline "Good People for Good Health" while managing this leadership transition.

In his farewell message, Chopra expressed gratitude to Board colleagues and management for their cooperation during his tenure, wishing the company success in its future endeavors. The structured approach to his departure demonstrates the company's focus on maintaining operational stability during leadership changes.

J B Chemicals and Pharmaceuticals Limited has published newspaper advertisements for the notice of equity shareholders meeting convened pursuant to the NCLT tribunal order dated March 23, 2026. The meeting is scheduled to consider and approve the proposed scheme of amalgamation with Torrent Pharmaceuticals Limited.

Shareholder Meeting Details

The company has published advertisements in Indian Express (English Language – All India Editions) and Sandesh (Gujarati Language - Gujarat Edition) on March 28, 2026. The equity shareholders meeting will be conducted through video conferencing or other audio visual means in compliance with applicable regulations.

E-Voting Schedule

The company has arranged remote e-voting facility for equity shareholders prior to the meeting. Physical attendance at the meeting has been dispensed with, and shareholders can participate through the digital platform.

NCLT Order Updates

The tribunal issued a corrigendum order on March 24, 2026, which was uploaded on the NCLT's official website on March 25, 2026. This follows the company's earlier intimation regarding the original order passed by the NCLT Ahmedabad Bench in connection with the proposed amalgamation.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Vice President – Secretarial Sandeep Phadnis signed the regulatory filing on March 28, 2026, informing BSE Limited about the newspaper advertisement publication.

Under the proposed scheme of amalgamation, J.B. Chemicals & Pharmaceuticals Limited will serve as the transferor company, while Torrent Pharmaceuticals Limited will act as the transferee company. The meeting notice and scheme documents are available on the company's website and stock exchange platforms for shareholder access.